Dr. Dean Rigel is a senior drug discovery scientist, in vivo pharmacologist/physiologist, and bioengineer with over 30 years of pharmaceutical and instrumentation/device experience. He obtained a PhD in Biomedical Engineering from Case Western Reserve University, joined Novartis and made significant contributions to enable 11 compounds to enter human clinical trials; some, including LCZ696/Entresto® and LCI699/Isturisa®, reached market.